Preservation of small bowel with the selective use of heparin and second look laparotomy in acute mesenteric ischaemia: A case report  by Fouad, Dina et al.
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INTRODUCTION:  Acute  mesenteric  ischaemia  may  occur  due  to  mesenteric  arterial  embolus,  thrombosis,
non-occlusive  mesenteric  ischaemia  or venous  thrombosis  resulting  in  ischaemia  of  the  bowel  wall.
PRESENTATION OF  CASE:  A 41 year  old woman  presented  with  worsening  abdominal  pain,  decreased
appetite,  nausea  and  vomiting.  Examination  revealed  right  lower  quadrant  tenderness.  Investigations
revealed  elevation  of  her inﬂammatory  markers.  At  laparotomy  two  separate  segments  of  ischaemic  but
potentially  viable  small  bowel  were  identiﬁed  secondary  to mesenteric  venous  thrombosis.  Bowel  salvage
was  attempted  with  the  use  of  intravenous  unfractionated  heparin  and this  was  conﬁrmed  following  a
second  look  laparotomy.
DISCUSSION:  Despite  a normal  platelet  count  at presentation  a diagnosis  of JAK-2  positive  essential
thrombocythaemia  was  made  thus  explaining  the  acquired  prothrombotic  state  underlying  the  venous
thrombosis.  The  selective  use  of  intravenous  unfractionated  heparin  and  second  look  laparotomy  may
provide  a means  for  bowel  preservation  in these  cases.
CONCLUSION: This  case  highlights  the  potential  of  bowel  salvage  can  be achieved  following  an  episode
of  acute  mesenteric  ischaemia  with  the  use  of  intravenous  unfractionated  heparin  and selective  second
look  laparotomy  and  the  importance  of  considering  underlying  myeloproliferative  disease  in such  cases
hrom
gical even  in the  absence  of  a t
© 2012 Sur
. Introduction
Acute mesenteric ischaemia occurs due to inadequate blood
ow through the mesenteric circulation causing ischaemia of the
owel wall. It occurs as a result of acute mesenteric arterial embolus
50%), acute mesenteric arterial thrombosis (25%), non-occlusive
esenteric ischaemia (15–20%) or mesenteric venous thrombosis
5–10%).1 The damage to the bowel wall can vary from reversible
schaemia to full thickness infarction resulting in necrosis and
erforation. Patients usually present with intense visceral pain dis-
roportionate to physical signs.
Acute mesenteric arterial emboli usually originate from a car-
iac source. Patients experience severe pain due to the sudden
ature of the occlusion. Mesenteric arterial thrombosis occurs
t the site of pre-existing atherosclerosis involving the superior
esenteric artery. Patients usually have a preceding history of
hronic mesenteric ischaemia before the acute thrombotic event,
recipitated by hypotension following a myocardial infarction
r arterial complications such as a dissection or trauma. Non-
cclusive mesenteric ischaemia occurs due to arterial spasm due to
∗ Corresponding author at: Department of Urology, Western General Hospital,
rewe  Road South, Edinburgh EH4 2XU, UK. Tel.: +44 7793954384.
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cardiogenic shock, septic shock, or hypovolaemia. Mesenteric
venous thrombosis often presents with acute abdominal pain in a
younger cohort. Symptoms may  be less dramatic, and the diagnosis
difﬁcult to establish. Most patients will have one or more risk fac-
tors for a generalised pro-thrombotic state. These risk factors may
be congenital or acquired and include hereditable thrombophilic
abnormalities such as deﬁciency of the natural anticoagulants
antithrombin and protein C and S or inheritance of the common
gain of function mutations factor V leiden and the prothrombin
gene G20210A mutation. Acquired prothrombotic states may  arise
locally from the abdominal cavity such as acute pancreatitis, active
inﬂammatory bowel disease, malignancy or sepsis or may result
from a systemic procoagulant state such as that resulting from the
use of the combined oral contraceptive pill or the development of
antiphospholipid syndrome or myeloproliferative disease.2
We  describe a case of acute ischaemia of the small bowel due
to mesenteric venous thrombosis secondary to essential throm-
bocythaemia, which was managed with intravenous heparin and
a second look laparotomy resulting in preservation of the small
bowel.
Open access under CC BY-NC-ND license.2. Presentation of case
A 41 year old Caucasian woman  presented to the General Surgi-
cal Unit with a 5 day history of continuing central abdominal pain
 BY-NC-ND license.
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nd gastrointestinal upset characterised by decreased appetite,
ausea and vomiting which had initially been treated as a gastritis
y her General Practitioner She had no signiﬁcant past medical his-
ory, in particular she had no personal or family history of venous
hromboembolism despite previous use of the combined contra-
eptive pill and a successful pregnancy. She had no features of
re-existing inﬂammatory bowel disease or overt liver disease. She
moked 20 cigarettes a day.
On examination she had a sinus tachycardia, a blood pressure
f 120/90 mmHg  and apyrexial. Abdominal examination conﬁrmed
ight lower quadrant tenderness. Blood results revealed elevation
f her inﬂammatory markers (white cell count: 24.8 and a C-
eactive protein: 87) and full blood count showed a haemoglobin
f 148 g/l and platelets of 175 × 109/l. Her chest, abdominal X-ray
nd ultrasound scan of abdomen were unremarkable.
With a presumptive diagnosis of appendicitis, a laparoscopy
as performed, however this was converted to a laparotomy in
ight of the ﬁndings. Two separate segments of small bowel 30 cm
n length in her distal and mid  small bowel were noted to be
schaemic but potentially viable. The mesenteric vessels supplying
hese two segments of small bowel appeared thrombosed but she
ad a good pulse in the origin of her superior mesenteric artery.
t was decided not to resect these segments at this stage but to
ommence therapeutic dose unfractionated heparin and perform a
econd look laparotomy 24 h later to assess bowel viability. At the
econd laparotomy, both previously noted ischaemic small bowel
egments appeared viable and resection was not required. The
atient was maintained on therapeutic heparin infusion. The use of
nfractionated heparin in this case was favoured because it offered
he option for rapid discontinuation and reversal in the event of
leeding.
In light of the surgical ﬁndings and the lack of an iden-
iﬁable intra-abdominal precipitant for the mesenteric vein
hrombosis the patient underwent investigations for a variety
f systemic prothrombotic disorders including; anti-phospholipid
yndrome, myeloproliferative disease and paroxysmal nocturnal
aemoglobinuria. The patient was found to have a mutation in JAK2
V617F positive) leading to a diagnosis of JAK2 positive myelopro-
iferative disease with a phenotype of essential thrombocythaemia
as established.
Prior to discharge she was commenced on cytoreductive ther-
py to reduce her platelet count to a normal range in the form of
ydroxycarbamide and formally anticoagulated with warfarin with
 view to maintaining an INR target of 2.5 long-term. These strate-
ies are designed to reduce the risk of future occlusive arterial and
enous events.
.  Discussion
Essential thrombocythaemia is a chronic myeloproliferative dis-
rder (MPD) characterised by an increase in the total number of
irculating platelets due to persistent megakaryocyte proliferation.
 mutation due to the substitution of valine to phenylalanine in
osition 617 of the JAK2, an important signalling protein, renders
ematopoietic cells more sensitive to growth factors such as ery-
hropoietin and thrombopoietin.3 Mutations in JAK2 are found in
pproximately 50–60% of cases of essential thrombocythaemia.4
he clinical manifestations of essential thrombocythaemia result
rom platelet activation,5 hyperviscosity, tissue hypoxia and vascu-
ar occlusion6 with arterial thrombosis occurring more commonly
han venous thrombosis.7 Mesenteric and portal vein thrombosis
re recognised rare complications of myeloproliferative disease.
tudies have reported that JAK2 V617F positivity can range from
2 to 74% in patients with splanchnic vein thrombosis.8,9 The diag-
osis of MPD  should be considered in these cases where there is noPEN  ACCESS
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other obvious local intra-abdominal precipitant of thrombosis even
when the FBC is normal as cases have been described where the
initial thrombotic event predated the development of the typical
peripheral blood count abnormalities which characterise MPD.10
The incidence of acute mesenteric ischaemia is difﬁcult to estab-
lish due to the lack of population based data, however, Acosta
reported an incidence of 12.9 per 100,000 person-years in a
Swedish cohort.11 It is likely that with an ageing population the
incidence will increase.12
The diagnosis of acute mesenteric ischaemia can at times be
difﬁcult to establish and often presents late with peritonitis. The
majority of patients will have a leucocytosis and an elevated
lactate level, however these ﬁndings are not speciﬁc to acute
mesenteric ischaemia.13 Computer tomography (CT) accurately
diagnosed mesenteric arterial occlusion or ischaemic bowel in 89%
of the patients while mesenteric angiography conﬁrmed mesen-
teric thrombosis or embolism in 94% of cases according to a study
by Park et al.14 We  would advocate the use of CT angiography to
evaluate patients thought to have acute mesenteric ischaemia.
Immediate revascularisation and/or removal of necrotic bowel
are the aims of therapy, with several options available depending
on the clinical scenario. These include: surgical management such
as arterial reconstruction or bypass, endovascular management
such as angioplasty and/or stenting or intraluminal thromboly-
sis, or medical management with intravenous heparin. In addition
bowel resection with immediate or delayed anastomosis may  be
required.15 Despite advances in diagnostic modalities and treat-
ments, the morbidity and mortality of acute mesenteric ischaemia
remains high, with studies reporting mortality rates between 53%
and 93%.9
During laparotomy, assessment of bowel viability is critical.
Simple measures such as intestinal colour, visible peristalsis and
mesenteric pulsations or more complex methods such as the use
of mesenteric colour duplex ultrasonography and the ﬂuorescein
uptake test can be used.16,17 Either way preservation of bowel is
critical as resection of potentially viable bowel can lead to compli-
cations at a later stage such as short bowel syndrome requiring long
term total parenteral nutrition and its associated complications.18
Second look laparotomy, carried out 24–48 h later, was  ﬁrst
introduced by Shaw in 1965 to allow reassessment at an early stage
on bowel viability. In addition it provides the opportunity to review
the effects of medical treatment such as intravenous heparin to
allow for potentially compromised bowel to become viable.19 A
recent review of studies evaluating second look operations for acute
mesenteric ischaemia found that although less than 50% of the
patients underwent a second look procedure, more than 40% ben-
eﬁted from this due to timely identiﬁcation of on-going pathology
and appropriate management at the time of the procedure.15
It can be argued that these patients should be managed
aggressively with the liberal use of second look laparotomies to
improve morbidity and mortality in this cohort. However, sec-
ond look laparotomies carry the disadvantages of a further general
anaesthetic, increased risk of wound complications and post-
operative infections. A study comparing planned re-laparotomy
with laparotomy on demand found planned re-laparotomy to have
an increased mortality rate.20 Therefore, second look laparotomies
should be carried out according to the clinical scenario.
4.  ConclusionThe occurrence of intra-abdominal venous and arterial throm-
bosis in association with a myeloproliferative disease prior to the
development of the typical peripheral blood phenotype is well doc-
umented. However, this case highlights the potential for bowel
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alvage following acute mesenteric ischaemia with the use of hep-
rin and selective second look laparotomy.
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